2 news items
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
GOVX
4 Apr 24
differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
GOVX
29 Feb 24
in 2022, with the increase primarily due to the costs of conducting clinical trials for GEO-CM04S1 and Gedeptin, costs of manufacturing materials
- Prev
- 1
- Next